AUA 2024
May 3 - 6, 2024 | San Antonio, TX
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
ARV-766, a PROTAC Androgen Receptor Degrader, Combined With Abiraterone in Novel Hormonal Agent–Naïve Metastatic Prostate Cancer: Phase 1 Cohort (Part C) of a Phase 1/2 StudyN Shore et al.